Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis-Reference-Cited by-同舟云学术

Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis

Published:2024-01-01 Issue:1 Volume:81 Page:85
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Kim John¹,Kesselheim Aaron S.¹,Bove Riley²,Avorn Jerry¹,Rome Benjamin N.¹

Affiliation:

1. Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

2. UCSF Weill Institute for the Neurosciences, Department of Neurology, University of California, San Francisco

Abstract

This cross-sectional study compares price data for ocrelizumab and rituximab to estimate the savings to Medicare and Medicaid if rituximab were used in the treatment of multiple sclerosis instead of the higher-priced ocrelizumab.

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2812354/jamaneurology_kim_2023_ld_230007_1703025849.89502.pdf

Reference5 articles.

1. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.;Hauser;N Engl J Med,2008

2. Raising Medicaid rebates for drugs with accelerated approval.;Rome;Health Aff (Millwood),2021

3. Estimates of Medicaid and non-Medicaid net prices of top-selling brand-name drugs incorporating best price rebates, 2015 to 2019.;Clemans-Cope;JAMA Health Forum,2023

4. Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis.;Roos;JAMA Neurol,2023

5. New approaches to challenge old assumptions: B-cell depletion in multiple sclerosis.;Oommen;JAMA Neurol,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Repurposing Via the Best Pharmaceuticals for Children Act;JAMA Pediatrics;2024-09-01

2. Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations;Revue Neurologique;2024-07

3. Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study;Annals of Neurology;2024-03-26